This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was:  Recruiting
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong Identifier:
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.

Condition Intervention
Pulmonary Veno-Occlusive Disease Hepatic Veno-Occlusive Disease Mucositis Drug: Glutamine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.

Resource links provided by NLM:

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]

Estimated Enrollment: 40
Study Start Date: July 2004
Estimated Study Completion Date: June 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00563498

Contact: YH Leung, Dr (852) 2855 3347

Queen Mary Hospital Recruiting
Hong Kong, China
Sub-Investigator: YH Leung, Dr         
Sub-Investigator: Raymond Liang, Prof         
Sponsors and Collaborators
Hospital Authority, Hong Kong
The University of Hong Kong
Fresienius Kabi HK Ltd
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
  More Information

Additional Information: Identifier: NCT00563498     History of Changes
Other Study ID Numbers: EC1432-00
Study First Received: November 21, 2007
Last Updated: July 6, 2010

Keywords provided by Hospital Authority, Hong Kong:
Veno-occlusive disease

Additional relevant MeSH terms:
Hepatic Veno-Occlusive Disease
Pulmonary Veno-Occlusive Disease
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases
Liver Diseases
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases processed this record on August 17, 2017